Related Experiment Videos
Latest developments in the field of neurotransmitters
1Department of Urology, The Royal Hallamshire Hospital, The University of Sheffield, Sheffield, UK. c.r.chapple@sheffield.ac.uk
European Urology
|August 15, 1998
Summary
Targeting neurotransmission receptors is key for new drug development. Understanding lower urinary tract diseases may lead to more specific therapies with fewer side effects.
Area of Science:
- Pharmacology
- Urology
- Drug Development
Background:
- Receptors in neurotransmission are crucial targets for drug development.
- Current therapies for bladder instability and benign prostatic hyperplasia utilize receptor antagonists.
- Further research into lower urinary tract disease pathophysiology is needed.
Purpose of the Study:
- To highlight the importance of receptor-specific compounds in drug development.
- To discuss the role of neurotransmission in lower urinary tract diseases.
- To explore the potential for tissue-specific drugs with reduced side effects.
Main Methods:
- Review of current pharmacological and molecular biological techniques.
- Analysis of established therapies targeting detrusor muscarinic and prostatic adrenergic receptors.
- Discussion of ongoing and future pathophysiological studies.
Main Results:
- Established therapies demonstrate the efficacy of receptor antagonism.
- Basic research is essential to understand neurotransmission's role in lower urinary tract diseases.
- Tissue-specific receptor properties are likely to be discovered.
Conclusions:
- Receptor-specific drug development is vital for treating lower urinary tract disorders.
- Future drug development will benefit from a deeper understanding of neurotransmission.
- Advances in pharmacology and molecular biology will enable more targeted therapies with improved safety profiles.